Luveltamab tazevibulin showed responses in platinum-resistant ovarian cancer in dose-optimization data; the trial was later terminated

Emerging ClinicalInvestigationalNot addressed

Luveltamab tazevibulin (luvelta), an investigational antibody-drug conjugate targeting folate receptor alpha (FRα), produced objective responses in patients with recurrent, platinum-resistant ovarian cancer in the dose-optimization portion of the phase 2/3 REFRaME-O1 trial (ClinicalTrials.gov NCT05870748), according to data presented at the Society of Gynecologic Oncology (SGO) 2025 annual meeting. At the selected dosing regimen (5.2 mg/kg every 3 weeks with prophylactic growth-factor support for the first two cycles, then 4.3 mg/kg every 3 weeks; n=25), the reported overall response rate was 32% and the disease control rate was 96%. A direct ClinicalTrials.gov registry query confirms this trial’s real, current status is TERMINATED — the randomized phase 3 comparison against investigator’s-choice chemotherapy, described as forthcoming in the original March 2025 presentation, did not proceed. Public reporting (company statements, trade press) attributes this to a March 2025 strategic portfolio decision by the drug’s developer, Sutro Biopharma, to deprioritize further internal investment in this specific ovarian-cancer program while seeking an external development partner — not a reported safety or efficacy failure of the dose-optimization data itself, which remains the last real result this trial produced. No FDA approval exists for this drug.

What This Means

In the dose-optimization portion of the now-terminated phase 2/3 REFRaME-O1 trial, the antibody-drug conjugate luveltamab tazevibulin produced objective responses in patients with platinum-resistant ovarian cancer expressing folate receptor alpha, at the dosing regimen selected for further study — a reported 32% overall response rate and 96% disease control rate in that specific 25-patient dosing cohort. That data remains real; the trial that would have confirmed it in a randomized comparison did not proceed.

What This Doesn't Mean

This is single-arm, dose-optimization-stage response data, not a completed randomized comparison, and this drug has no FDA approval. The trial was terminated before its planned randomized phase 3 portion (luveltamab vs. investigator's choice chemotherapy) began — that comparison will not report results, and this record makes no claim about how luveltamab compares to standard chemotherapy. Termination reflects a reported sponsor portfolio decision, not a disclosed safety or efficacy failure — but readers should not assume this drug will reach approval or further study without a new sponsor or partner.

Why It Matters

A real, meaningful response rate in previously-treated, platinum-resistant ovarian cancer — a setting with historically poor outcomes and limited options — that will not be confirmed by this trial's own randomized comparison. Illustrates a genuine, common pattern in drug development worth naming honestly: promising early data does not guarantee continued investment.

Promise & Proof

Proof — strength of the evidence 3 / 5

Base score from evidence stage: Emerging Clinical.

Promise — potential significance if later evidence holds up 3 / 5

Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
The record includes substantive editorial reasoning about why this discovery matters.
Targets a cancer type with historically limited effective treatment options.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with recurrent, platinum-resistant ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing folate receptor alpha (FRα), who received 1-3 prior lines of therapy, enrolled in the dose-optimization portion of a phase 2/3 trial that has since been terminated before its planned randomized phase 3 portion began (see correction_note). Efficacy figures here are from the 25-patient cohort receiving the dosing regimen originally selected for further study. (Adults)

Eligibility was restricted to FRα-expressing tumors, and this is an early-stage, dose-optimization result from a small cohort (n=25) that was never followed by a randomized comparison — should not be presented as an established treatment option or as equivalent-strength evidence to a completed randomized trial. This record's trial-status framing was corrected after direct verification found the trial terminated; re-check registry status again before any future republication in case a new sponsor resumes development.

Full evidence details

Study design: Non-randomized trial
Sample size: 25

Funding & Conflicts

Original sponsor: Sutro Biopharma. Public reporting indicates Sutro deprioritized further internal investment in this program in March 2025 while seeking an external development partner — not independently confirmed against a primary corporate-disclosure document (e.g. an SEC filing).

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-13

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position: Not addressed
Last verified: 2026-08-13

Primary evidence supporting this story

REFRaME-O1 trial registry (phase 2/3 study of luveltamab tazevibulin in platinum-resistant ovarian cancer) (opens in a new tab) (Clinical-trial registry) NCT05870748 Load-bearing source NCT05870748
REFRaME-O1 trial registry (phase 2/3 study of luveltamab tazevibulin in platinum-resistant ovarian cancer). NCT05870748.

Why Should I Trust This?

1 source at Tier 1 — Government/regulatory authority (FDA, NCI, NIH, ClinicalTrials.gov, CDC, and equivalent)
Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

2026-08-13 Status change — Status changed from "Legacy / Unverified" to "In editorial review".
2026-08-13 Status change — Status changed from "In editorial review" to "Verified".

Last reviewed 2026-08-13